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e field of genomic medicine continues to expand, 
driven by the efforts of numerous researchers around the 
world. To celebrate Genome Medicine’s 2nd anniversary, 
we asked our Section Editors what they felt were the 
most exciting breakthroughs in research in the past 
2 years and what the future of genomic medicine might 
hold.
Transformational eect of systems medicine
Since we discussed systems medicine as the future of 
medical genomics and healthcare in the inaugural issue 
of Genome Medicine [1], the field has witnessed trans-
formational changes that have brought the prospect and 
promises of personalized medicine closer to reality. e 
exponential increase in DNA sequencing capabilities, 
together with the rapidly declining associated costs, has 
made whole-genome sequencing accessible to small 
labora tories, and will soon transform it into a low cost 
analytical assay. ese advances have enabled the emer-
gence of medical systems genetics studies, an approach in 
which the genetic determinants of diseases are investi-
gated through sequencing of the complete genome of 
family relatives. For example, sequencing and analysis of 
the genomes of two siblings and their parents made 
possible the direct measurement of the inter-generational 
mutation rate and identified genes potentially associated 
with two Mendelian disorders [2]; the gene causing one 
of these disorders was precisely identified through further 
exome sequencing in additional diseased patients [3]. 
Another telling example of both the power and current 
limitations of the next-generation sequencing approaches 
is their application to the characterization of the genome, 
epigenome and transcriptome of monozygotic twins 
discordant for multiple sclerosis, which failed to uncover 
significant differences associated with the disease [4]. 
With several thousand genomes now being completed, 
and tens of thousands anticipated in the coming year, the 
limitation is already to a large extent, and will increasingly 
be, on the side of data analysis, as the collection, storage 
and analysis of the large datasets generated requires the 
combined expertise of a wide variety of scientists, 
engineers and physicians [5]. Fortunately, the software, 
databases and computing power required for these 
community efforts are now becoming available through 
computer grids and cloud computing infrastructures, 
offering an affordable alternative for genome and trans-
lational bioinformatics [6,7]. Combined together, genome 
sequencing and cloud computing will contribute to 
bridging the gap between systems biology and medicine 
by opening the way to the precise and low cost assays that 
are necessary for systems medicine to become a practical 
alternative to traditional reactive medicine [8].
Charles Auffray, Section Editor, 
Systems medicine and informatics
The public perception challenge
Public perception research has long been a big part of the 
ethical, legal and social issues (ELSI) research agenda. 
Over the past decades a wide range of methods have been 
deployed to tease out how the public (whatever that 
might be) feels about everything from gene patents to 
genetic privacy to the utility of direct-to-consumer test-
ing services. However, understanding public percep tions 
has never been more important than it is now. Genomic 
research requires even more research partici pants, 
through such initiatives as large population bio banking 
studies. And the clinical value of many proposed genomic 
interventions depends on a public response to gene-
based risk information (such as the promotion of healthy 
lifestyle changes). Understanding how the public views 
and is likely to respond to genetic information will have 
an impact on both the nature of research that can be 
done and whether we will derive social benefit from that 
research. Recent public perception research has demon-
strated that the challenges in both of these areas could be 
profound. For example, a study that included 16 focus 
groups and a survey of over 4,000 individuals concluded 
that the public wants ongoing control over their genetic 
samples that have been donated for research [9]. Subse-
quent studies have come to similar results [10]. People 
want ‘control.’ ey want to consent. But can we give 
mean ing to this public desire and still carry out big 
genomic studies? e research on how people respond to © 2010 BioMed Central Ltd
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genomic information is also illuminating and somewhat 
deflating, at least from a public health perspective. The 
emerging data, wonderfully summarized in a recent 
Cochrane Collaboration review [11], highlights that the 
public response to genetic risk information seems likely 
to be rather muted [12]. Given this reality, at least one 
aspect of the long promised benefits of genomics­
informed personalized medicine ­ that is, the promotion 
of individualized preventive health strategies ­ may not 
pan out as expected. What is probably needed is both a 
more realistic appraisal of how genetic information will 
assist approaches to public health and more research into 
the ways in which genetic information can supplement, if 
at all, existing disease risk information.
Timothy Caulfield, Section Editor, 
Social, ethical and legal issues in genomic medicine
The translational gap in genomic medicine
Rapid advances in genomics and related technologies are 
promising a new era of personalized healthcare and 
disease prevention, including new drugs, diagnostic and 
screening tests based on individual genetic makeup and 
disease biomarkers. Scientists predict that the age of 
persona lized health care has arrived. Nevertheless, the 
gap is still wide between new discoveries and their 
clinical validity and utility in practice [13]. The expansion 
of direct­to­consumer marketing of personal genome 
profiles for risk assessment and disease prevention illus­
trates the premature deployment of this technology 
without the appropriate evidence base to support their 
use in practice [14]. If the promise of genomics is to be 
fulfilled, we must use scientific methods to document 
how such technologies can improve health and prevent 
disease in practice. Dealing with the genomics evidence 
gap will require two key and interrelated science and 
policy areas, which are crucial to accelerating the appro­
priate translation of genomics into clinical practice. The 
first is to develop a multidisciplinary translation research 
agenda, including more clinical and population­based 
research, in the life cycle of research from the bench to 
improved population health outcomes [15,16], and the 
second is to develop a stakeholder collaboration to effect 
evidence­based translation. Translation research is 
necessary, but not sufficient, to move specific genomic 
applications from research into practice. Actual trans­
lation is even more complicated. Different forces can 
accelerate or impede the translation process, such as 
private investments in research and development, policy 
and legal frameworks, oversight and regulation, product 
marketing, coverage and reimbursements, consumer 
advocacy, provider awareness, access, and health services 
development and implementation [17,18].
Muin Khoury, Section Editor, 
Genomic epidemiology and public health genomics
Genome Medicine and personal genomics
In order for the discipline of genomic medicine to fulfill 
its maximum potential and utility in the clinic, it is 
necessary to be able to characterize all forms of genetic 
variation in an individual patient’s genome. This includes 
single or simple nucleotide variation (SNV) and copy 
number variation (CNV). Personal genome sequencing is 
becoming a reality. The complete nucleotide sequence of 
James Dewey Watson, 55 years after his discovery of 
DNA and two decades after he led the human genome 
project, provided tremendous insights into personal 
genomes. It was the first human genome sequenced by 
next generation sequencing [19] and revealed extensive 
variation: greater than 3 million SNV differences in 
comparison with the reference haploid human genome 
sequence and a high frequency of small sized CNVs (less 
than 1 kb) that were beyond the detection limits of array 
comparative genomic hybridization. Another major find­
ing was the amount of Alu repetitive element polymorph­
isms ­ indels (insertions or deletions) representing 
dimor phisms of Alu at a particular locus. Thus, for each 
personal genome the amount of structural variation related 
to the position of repetitive elements could be immense. 
The remarkable extent of genome structural variation in 
populations was further revealed by Conrad et al. [20].
The next important step in personal genomics was to 
use whole­genome sequence to associate specific varia­
tion with clinical disease phenotypes, and thus identify 
medically actionable variation from the myriad of benign 
polymorphic variations; that is, detect signal from noise. 
Whole­genome sequencing (WGS) was used to identify 
the cause of Charcot­Marie­Tooth neuropathy. Surpris ingly, 
this work also provided insights into genetic variation 
underlying common complex traits such as carpal tunnel 
syndrome [21]. Whole exome sequencing (WES) has 
also now been used to find the medically actionable 
alleles in defined clinical Mendelian phenotypes for 
which the causative genes were unknown (for example, 
[3,22­24]), and to make a definitive diagnosis for a 
patient with a complex trait [25]. Further exome 
sequencing work recently documented that new 
mutations may contribute in a significant way to 
common traits such as mental retardation and 
intellectual disability [26]. This latter study emphasizes 
the importance of personal genomics for assessing not 
only inherited variation but also de novo events.
However, we must not lose sight of the challenges! 
Exome sequencing provides essentially no information 
about structural variation and CNV. Whole­genome 
sequenc ing can provide structural variation information, 
but it is not obvious to what extent short read sequences 
can capture CNV, such as those of only a few hundred 
base pairs that may delete or duplicate single exons [27] 
or delineate complex rearrangements, given the 
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informa tion filtering step required in matching short 
reads to a haploid human reference genome. Whether or 
not WES or WGS will discern repeat expansion, a highly 
significant form of pathology­associated genetic 
variation, also remains to be demonstrated. Nevertheless, 
from the insights already provided, it is clear that the 
information that can be gleaned from personal genome 
sequencing will probably be so compelling that clinicians 
will be motivated to rapidly adapt it into clinical practice.
James R Lupski, Section Editor, 
Molecular genetics, genomics and epigenetics of disease
The paradigm-shift of personalized medicine
The modern concept of personalized medicine is 
stimulated by the idea that genomic medicine may help 
to prevent and/or treat diseases by the use of the 
individual genetic information of the host, tumor and/or 
other biological organisms (such as bacteria). Pharmaco­
genomics, a distinct discipline within the field of 
personalized medicine, includes the study of the 
influence of genetic variation on drug response, but also 
comprises the genome­wide and multi­factorial exten­
sion. Thus, in the modern conception of personal ized 
medicine, the tools that are provided to the physician are 
hopefully more precise, considering not just the obvious, 
such as a malign tumor by computer tomography, but the 
individual genetic make­up of the patient. There are 
several examples in which a profile of a patient’s genetic 
variation is used to guide the selection of drugs or 
treatment processes, leading to a more successful out­
come from the medical treatment [28]. The question is 
no longer what if this could happen in clinical practice, 
but when. Consideration of new ‘omics­based biomarkers 
for patient stratification should by no means exclude the 
use of traditional biomarkers, such as a patient’s age, 
body composition, physical examination findings, blood 
pressure, and so on, for diagnosis of disease and choice of 
prevention or treatment. However, personalized treat­
ment needs to combine clinical assessment and disease 
diagnostic tests with treatment­related (genetic) tests. In 
addition to biomarkers predicting the efficacy and, if 
possible, effectiveness of a treatment, sufficient attention 
must also be given to the use of biomarkers for predicting 
drug safety. Considerable research activities in biomarker 
discovery and validation are ongoing, but little is being 
done to bring this information into clinical practice [29]. 
The cost of sequencing the human genome falls and 
whole­genome sequencing is already occurring, but data 
interpretation requires expertise not only related to the 
genetics of disease, but also related to pharmacological 
principles. Continuing Medical Education courses on 
personalized medicine, particularly with focus on 
genomic issues, need to be made available to bring 
physicians to the latest technological developments. To 
this end there is still a substantial need to demonstrate 
the potential added value that personalized genomic­
based approaches bring, in particular the added value of 
patient stratification in view of improved effectiveness 
and/or reduction of adverse side effects.
Matthias Schwab, Section Editor, 
Personalized medicine and therapeutics
From sensitive technologies to clinical action
Undoubtedly the greatest advances in translational 
medicine over the past decade have been in the area of 
genetics. The advent of next­generation sequencing tech­
nologies have made genome­wide association studies, the 
identification of large numbers of single nucleotide 
polymorphisms and copy number variants that influence 
disease possible. In the post­genomic era, the hope is that 
advances in proteomic measurements can mimic those 
made in genetics. Although progress has not been as 
dramatic, technologies for protein measurements are 
making important strides in translational medicine. If 
proteomic technologies are to have an impact on 
translational medicine, however, they must be adaptable 
to analyzing clinic samples. This requirement means 
analyzing small volumes of biofluids and thin tissue 
sections, both fresh frozen and formalin­fixed. One of the 
most important developments to achieving this goal is 
the increasing sensitivity provided by mass spectro­
meters. In the past highly sensitive mass spectrometers 
were limited to specialized mass spectrometry (MS) 
laboratories. Nowadays, instruments that routinely 
measure sub­femtomole levels of proteins in complex 
biological matrices are being widely used in traditionally 
non­MS laboratories. Thousands of proteins can now be 
identified from as little as 100 µl of blood [30]. Laser 
capture microdissection of approximately 5,000 cells 
from thin tissue sections can now provide upwards of 
2,500 confident protein identifications [31]. With the 
develop ment of methods to extract proteins from 
formalin­fixed tissue sections, MS can now analyze a 
seemingly inexhaustible source of tissues from countless 
tumor types [32]. The sensitivity provided by modern mass 
spectrometers leads to greater proteomic coverage for 
identifying disease­specific biomarkers and enhancing the 
quantitative measurement of specific proteins in clinical 
samples. Unfortunately, increased sensitivity com pounds 
an existing problem specifically in the use of MS for the 
discovery of disease­specific biomarkers: turning data into 
information. The next big development in post­genomic 
medicine will be devising methods or bioinformatic tools 
to recognize potentially valuable protein biomarkers in the 
complex datasets generated using MS.
Timothy D Veenstra, Section Editor, 
Post-genomic advances in medicine
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